Study design
ICH
We conducted an 8-week open-label, multi-center, dose-escalating phase I study in patients with pretreated progressive MM. The study was registered under EUdraCT number 2014–005137-32 and approved by both the Independent Ethics Committee at the Medical Faculty of RWTH Aachen University and the Federal Institute for Drugs and Medical Devices (BfArM) and conducted in accordance with the ethical principles of ICH’s Good Clinical Practice guidelines and the Declaration of Helsinki (